Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-02
2008-10-28
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S012200, C530S300000, C530S303000, C530S308000, C530S324000, C564S236000
Reexamination Certificate
active
07442682
ABSTRACT:
Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.
REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 5766620 (1998-06-01), Heiber et al.
patent: 5882675 (1999-03-01), Ninomiya et al.
patent: 6146656 (2000-11-01), Hori et al.
patent: 6669951 (2003-12-01), Rothbard et al.
patent: 6703359 (2004-03-01), Young et al.
patent: 7060708 (2006-06-01), Piccariello et al.
patent: 2003/0032593 (2003-02-01), Wender et al.
patent: WO 03/049772 (2003-06-01), None
patent: WO 03/072195 (2003-09-01), None
patent: WO 2005/000222 (2005-01-01), None
patent: WO 2005/117584 (2005-12-01), None
Pi-interaction from www.chemsoc.org/ExemplarChem/entries/2004/warwick-robinson/Pi.htm.
Boger RH and Bode-Boger SM, The Clinical Pharmacology of L-Arginine, Annu. Rev. Pharmacol. Toxicol., 2001, 41: 79-99.
Daibetes, Heart Disease and Stroke, from www. diabetes.org/heart-disease-stroke.jsp.
Drucker, “Enhancing Incretin Action for the Treatment of Type 2 Diabetes,”Diabetes Care, vol. 26, No. 10, pp. 2929-2940, Oct. 2003.
Kim, et al. “Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate,”Diabetes, vol. 52, pp. 751-759, Mar. 2003.
Knudsen, “Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes,”Journal of Medicinal Chemistry, vol. 47(17): pp. 4128-4134, Aug. 12, 2004.
Kolterman, et al. “Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes,”The Journal of Clinical Endocrinology&Metabolism, vol. 88, No. 7, pp. 3082-3089, 2003.
Nielsen, et al. “Pharmacology of Exenatide (Synthetic Exendin-4) for the Treatment of Type 2 Diabetes,”Current Opinion in Investigational Drugs, vol. 4, No. 4, pp. 401-405, Apr. 2003.
Orskov, et al. “Pharmacokinetic, Insulinotropic, and Glucagonostatic Properties of GLP-1 [7-36 amide] After Subcutaneous Injection in Healthy Volunteers. Dose-Response-Relationships,”Diabetologia, vol. 38, No. 6, pp. 720-235, Jun. 1995 (Abstract only).
Stoffers, et al. “Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat,”Diabetes, vol. 52, pp. 734-740, Mar. 2003.
Thorkildsen, et al. “Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression indb/dbMice,”The Journal of Pharmacology and Experimental Therapeutics, vol. 307, No. 2, pp. 490-496, 2003.
Zander, et al. Effect of 6-week Course of Glucagon-Like Peptide4 1 on Glycaemic Control, Insulin Sensitivity, and β-cell Function in Type 2 Diabetes: A Parallel-Group Study,The Lancet, vol. 359, pp. 824-830, Mar. 9, 2002.
“Liraglutide.” Article downloaded from the glucagon.com website, dated Aug. 30, 2004, 3 pages.
Review article by Nuria Morral inTrends in Endocrinology and Metabolism, May 2003, regarding Newer Approaches to the Treatment of Type 2 Diabetes.
Rothbard, et al. “Conjugation of Arginine Oligomers to Cyclosporin A Facilitates Topical Delivery and Inhibition of Inflammation,”Nature Medicine, vol. 6, No. 11, pp. 1253-1257, Nov. 2000.
Hou Zheng
Kagehisa Natsuko
Kamiyama Masashi
Kitaura Chieko
Liu Jian
Gupta Anish
Ha Julie
Knobbe Martens Olson & Bear LLP
Nitto Denko Corporation
LandOfFree
Transepithelial delivery of peptides with incretin hormone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transepithelial delivery of peptides with incretin hormone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transepithelial delivery of peptides with incretin hormone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994815